Systems biology approaches to dissect regulatory pathways in cancer

Cancer cells acquire genetic and epigenetic alterations that often lead to dysregulation of oncogenic signal transduction pathways, which in turn alters downstream transcriptional programs. The wealth of genomic data generated in the past decade from analyses of thousands of tumor samples has highlighted dramatic heterogeneity between, and within, single tumors. Understanding this diversity —and especially of its impact on tumor biology and cancer therapy— is still limited. We will present recent computational methodologies from our group to leverage heterogeneous omics, drug response and clinical data for deciphering regulatory pathways to study inter-patient population subtypes and intra-tumor heterogeneity.